ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Eris Lifesciences has entered into a term loan agreement with Axis Bank Limited for ₹45 Crore to meet general liabilities.
Eris Lifesciences Limited has drawn down a ₹64.40 Crore working capital term loan from Axis Bank. The funds will be used to meet existing short-term liabilities.
Eris Lifesciences paid ₹109.12 Crore in gross interest for two NCD series. This routine debt servicing confirms the company's ability to meet its ongoing financial obligations.
Eris Lifesciences fixed May 24, 2026, as the record date for NCD interest payments. Payments for two ISINs are scheduled for June 8, 2026.
Eris Lifesciences Limited submitted its annual disclosure for the centralized database of corporate bonds/debentures for the financial year ended March 31, 2026. The report details two outstanding NCD series (ISINs: INE406M08011 and INE406M08029) listed on the BSE, confirming timely interest payments and no defaults during the period.
Eris Lifesciences Limited submitted its half-yearly statement for debt securities ended March 31, 2026. The company has two outstanding NCD issuances totaling ₹1,250 Crore, with coupon rates of 8.73% and maturities in 2026 and 2027. This filing ensures compliance with SEBI reporting norms for listed debt instruments.